Fortunately, the main goal of the treatment was reduction of the disabling orofacial peak‐dose dyskinesia, therefore, targeting the GPi was considered appropriate irrespective of the technique applied, DBS, or MRgHiFUS. This evidence concerns the gene GPI and drug-induced dyskinesia.